Riyadh Valley Company

Envisioned to help transform Saudi Arabia's oil-based economy into a revolutionary knowledge-based economy, Riyadh Valley Company is one of Saudi Arabia's mega initiatives to support the adoption of innovation culture, foster entrepreneurship, leverage the kingdom's research capabilities, mobilize, engage and oversight investments in knowledge-based sectors.

Khalid Al-Saleh

CEO

13 past transactions

Noon Academy

Series B in 2023
Noon Academy operates an online learning platform that focuses on enhancing educational experiences for students in the Middle East. Founded in 2013 and headquartered in Riyadh, Saudi Arabia, with offices in Cairo, Egypt, and Bengaluru, India, the platform has successfully taught 12 million students. It offers a blend of free educational content and tutoring services, allowing students to study collaboratively in groups, compete with peers, and request on-demand tutoring. The platform is designed to prepare students for various examinations, including general aptitude and achievement tests. Additionally, Noon Academy supports teachers by enabling them to build followings and earn income based on their performance and student feedback. By integrating elements of peer-to-peer learning and advanced technology, Noon Academy aims to provide equitable access to high-quality education for every student.

TruKKer

Series C in 2022
TruKKer is a technology-enabled truck aggregator founded in 2016 and based in Abu Dhabi, UAE. The company operates a logistics and fleet management platform that simplifies road freight and logistics operations by connecting shippers with available trucks in real-time. This integration of supply and demand enhances asset utilization, reduces transportation costs, and provides reliable cross-border services. TruKKer's cloud-based freight solutions offer comprehensive coverage and a full-service portfolio for shippers, carriers, and businesses, leveraging real-time data analytics to ensure transparency and efficiency. The company’s rapid growth has opened up opportunities for data monetization and consolidated procurement, further solidifying its position in the logistics market.

Rutilea

Series B in 2022
Rutilea is an IT company focused on addressing social challenges through open-source solutions. It specializes in developing a zero-code task recognition system that enhances operational efficiency, quality, and safety across various industries. Utilizing multimodal artificial intelligence, Rutilea's system accurately identifies tasks in diverse environments, facilitating automation in factories and retail settings. This approach empowers businesses to make data-driven decisions and significantly improve productivity. By advancing the concept of "AI teaching AI," Rutilea aims to redefine automation and operational processes, contributing to a more efficient and effective work environment.

Prokarium

Series B in 2020
Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions utilizing synthetic biology. The company’s product pipeline includes Vaxonella, which is designed to enhance immune responses through its unique delivery method involving micro fold cells in the small intestine. Prokarium is also working on vaccines targeting Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. With a focus on microbial immunotherapy, Prokarium aims to revolutionize cancer treatment, particularly in bladder cancer, by creating immune-driven, long-lasting antitumor effects. Founded in 2007, Prokarium is committed to advancing the field of immuno-oncology through innovative approaches that harness the power of synthetic biology.

SecuLetter

Series B in 2020
SecuLetter Co Ltd is a company focused on providing advanced solutions to combat cyber threats, including malware and phishing attacks. The company employs hybrid approaches that integrate both static and dynamic analysis to detect unknown attacks, even as cyber criminals increasingly try to conceal malicious content within emails. SecuLetter specializes in diagnosing and analyzing security vulnerabilities at the assembly level, which allows for a detailed examination of non-executable files, resulting in a high detection rate for security threats and vulnerabilities. Its primary business areas encompass email security, secure data transmission between networks, web service file protection, document centralization security, cloud support security, and security threat intelligence. The company's commitment to delivering fast and accurate diagnostics positions it as a leader in the cybersecurity field.

SecuLetter

Series B in 2019
SecuLetter Co Ltd is a company focused on providing advanced solutions to combat cyber threats, including malware and phishing attacks. The company employs hybrid approaches that integrate both static and dynamic analysis to detect unknown attacks, even as cyber criminals increasingly try to conceal malicious content within emails. SecuLetter specializes in diagnosing and analyzing security vulnerabilities at the assembly level, which allows for a detailed examination of non-executable files, resulting in a high detection rate for security threats and vulnerabilities. Its primary business areas encompass email security, secure data transmission between networks, web service file protection, document centralization security, cloud support security, and security threat intelligence. The company's commitment to delivering fast and accurate diagnostics positions it as a leader in the cybersecurity field.

Prokarium

Series A in 2018
Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions utilizing synthetic biology. The company’s product pipeline includes Vaxonella, which is designed to enhance immune responses through its unique delivery method involving micro fold cells in the small intestine. Prokarium is also working on vaccines targeting Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. With a focus on microbial immunotherapy, Prokarium aims to revolutionize cancer treatment, particularly in bladder cancer, by creating immune-driven, long-lasting antitumor effects. Founded in 2007, Prokarium is committed to advancing the field of immuno-oncology through innovative approaches that harness the power of synthetic biology.

Fastned

Post in 2016
Fastned B.V. is a company that constructs and operates fast-charging stations for electric vehicles, primarily in the Netherlands and Germany, with additional operations in the United Kingdom, France, Switzerland, and Belgium. Founded in 2012 and headquartered in Amsterdam, Fastned focuses on providing charging services that utilize renewable energy sources such as solar and wind power. The company aims to establish a European network of 1,000 charging stations located in prime areas, allowing drivers of all-electric vehicles, including popular models like Tesla, Nissan, BMW, and Hyundai, to charge efficiently. In addition to its charging station operations, Fastned also engages in the buying and selling of charging equipment.

Sol Voltaics

Series C in 2016
Sol Voltaics AB is a nanotechnology company based in Lund, Sweden, that specializes in enhancing the efficiency of solar energy capture and generation. Established in 2007, the company develops and commercializes innovative nanomaterials, particularly through its flagship product, SolFilm. This solar panel additive, composed of gallium arsenide nanowires, is designed to improve the performance of conventional silicon solar modules. SolFilm is lightweight and transparent to infrared light, allowing it to convert high-energy sunlight directly into electricity while enabling additional power generation through underlying solar cells in a stacked configuration. By integrating these advanced technologies, Sol Voltaics aims to significantly boost the efficiency of photovoltaic modules, potentially increasing their output by up to 50%.

Sol Voltaics

Grant in 2016
Sol Voltaics AB is a nanotechnology company based in Lund, Sweden, that specializes in enhancing the efficiency of solar energy capture and generation. Established in 2007, the company develops and commercializes innovative nanomaterials, particularly through its flagship product, SolFilm. This solar panel additive, composed of gallium arsenide nanowires, is designed to improve the performance of conventional silicon solar modules. SolFilm is lightweight and transparent to infrared light, allowing it to convert high-energy sunlight directly into electricity while enabling additional power generation through underlying solar cells in a stacked configuration. By integrating these advanced technologies, Sol Voltaics aims to significantly boost the efficiency of photovoltaic modules, potentially increasing their output by up to 50%.

Saudi Smart Electronics

Venture Round in 2016
Saudi Smart Electronics specializes in the manufacturing of smart meters that accurately measure electricity consumption. These advanced meters are designed to notify users of peak consumption periods and are connected to the national grid. This connectivity allows clients to make informed decisions regarding electricity conservation, ultimately promoting energy efficiency. By focusing on innovative technology, Saudi Smart Electronics aims to enhance the management of electricity usage for its customers.

Knowledge Developers

Venture Round in 2015
Knowledge Developers is an information technology firm that specializes in providing software and web application development, alongside comprehensive business management and IT services. The company focuses on creating IT products that ensure accessibility across various computer devices, which helps clients streamline their operations and enhance connectivity with existing systems. By addressing the growing demand for software support, Knowledge Developers aims to simplify information access and improve overall efficiency for its clients.

Avidity Biosciences

Venture Round in 2014
Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.